Page 1

Exhibit 99.1 Zynex Announces 2021 First Quarter Earnings 2021 First Quarter 0 Revenue increased 58 % year over year to $ 24.1 million 0 Orders increased 140 % 0 Net loss of $ 0.7 million ; GAAP loss per share $ 0.02 0 Adjusted EBITDA loss $ 0.4 million - ENGLEWOOD , CO – April 29 , 2021 – Zynex , Inc. ( NASDAQ : ZYXI ) , an innovative medical technology company specializing in the manufacture and sale of non - invasive medical devices for pain management , stroke rehabilitation , cardiac monitoring and neurological diagnostics , today reported financial results for its first quarter ended March 31 , 2021 . First Quarter Financial Results Summary : For the first quarter , the Company reported net revenue of $ 24.1 million , a 58 % increase over the first quarter of 2020. Gross margins were 76 % in the first quarter of 2021 and net loss was $ 0.7 million . There was an Adjusted EBITDA loss of $ 0.4 million in the first quarter of 2021 . As of March 31 , 2021 , the company had working capital of $ 51.5 million . Cash on hand was $ 33.4 million at the end of the first quarter . Cash decreased during the quarter due to the company maintaining higher than normal inventory levels to protect against any supplier delays related to COVID - 19 . There have not been any issues with supplier deliveries to date . President and CEO Commentary : Thomas Sandgaard , CEO said : “ I am excited about our order growth in the first quarter of 140 % which will continue to drive increasing revenue throughout 2021 and 2022. In the first quarter , we posted revenue of $ 24.1 million . First quarter revenue is historically affected by health insurance deductibles not being met in the beginning of the year . The combination of seasonality of deductibles along with the sales force investments we made during 2020 produced a small loss in Q1 which was expected . Profitability is expected to ramp quickly beginning in second quarter with projected Adjusted EBITDA of over $ 3 million . In the first quarter , we focused on productivity of our existing sales reps and trimmed our sales force slightly below 500. We still expect to have over 600 sales reps by the end of 2021 with most of those additions coming in the second half of the year . We continue to advocate for pain patients , and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects . We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids . " Second Quarter and Full Year 2021 Guidance : The estimated range for second quarter revenue is between $ 31.0 and $ 32.5 million with Adjusted EBITDA between $ 3.0 and $ 4.0 million . The revenue estimate is approximately 61 % to 69 % above 2020 second quarter revenue of $ 19.3 million . Full year 2021 revenue is estimated between $ 135.0 and $ 150.0 million with Adjusted EBITDA between $ 15.0 and $ 25.0 million . The full year revenue estimate is approximately 68 % to 87 % above 2020 revenue of $ 80.1 million . We expect profitability to continually ramp throughout the year to meet our Adjusted EBITDA forecast of $ 15 to $ 25 million for 2021 .